



Cinacalat 30

Tablets

Cinacalcet I.P. 30 mg



Effective PTH Control

Cinacalcet helps reduce parathyroid hormone (PTH) levels effectively in secondary hyperparathyroidism.¹



Supports Bone Health

Helps improve bone turnover markers and supports overall bone health in CKD patients.²



Calcium Regulation

Effectively lowers serum calcium levels to maintain calcium balance.³



For CKD Patients

Indicated for patients with chronic kidney disease on dialysis with secondary hyperparathyroidism.⁴



Well Tolerated

Generally well tolerated with a manageable side effect profile.⁵

INDICATIONS

Secondary Hyperparathyroidism in CKD

CKD Patients on Dialysis

Management of Elevated PTH Levels

Calcium Balance in CKD

References:

1. Drüeke TB, Massy ZA. Cinacalcet: a calcimimetic agent for the treatment of secondary hyperparathyroidism. *Nephrol Dial Transplant*. 2008;23(2):322–330.
2. Messa P, Reginato AJ, Block GA. Cinacalcet HCl and the management of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. *Kidney Int*. 2008;74(8):1063–1070.
3. Moe SM, Chertow GM, Coburn JW, et al. Cinacalcet, calcium, phosphorus, and parathyroid hormone in end-stage renal disease. *J Am Soc Nephrol*. 2005;16(3):800–807.
4. KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). *Kidney Int Suppl*. 2017;7(1):1–59.
5. Peacock M, Bilezikian JP, Klassen PS, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in dialysis patients. *Kidney Int*. 2005;68(1):179–186.